Get 40% Off
🚀 Our AI Picked 6 Stocks that Jumped +25% in Q1. Which Picks Will Soar in Q2?Unlock full list

C4X Discovery Holdings signs licensing agreement with Sanofi, shares jump

Published 12/04/2021, 09:39
Updated 12/04/2021, 09:42
© Reuters.

By Samuel Indyk

Investing.com – C4X Discovery Holdings PLC (LON:C4XD), a UK-based pharmaceutical company, announced today that its subsidiary C4X Discovery Limited has signed an exclusive global licensing agreement with French pharmaceutical company Sanofi (PA:SASY) for its oral pre-clinical IL-17A inhibitor programme.

Financial terms

C4X will receive an upfront payment of €7mln from Sanofi, plus €11mln in pre-clinical payments. The company could also receive a further €407mln if certain development, regulatory and commercialisation milestones are met, meaning the total value of the deal is up to €414mln.

Treatment

The IL-17 family of cytokines are strong inducers of inflammation and are implicated in a variety of autoimmune diseases including psoriasis, psoriatic arthritis and ankylosing spondylitis. Under the license, Sanofi will develop and commercialise an oral therapy for the treatment of these inflammatory diseases.

“We are proud to be working with Sanofi to create much needed oral therapies in the underserved inflammatory disease space.,” said C4X Discovery CEO Clive Dix. “The Psoriasis market alone is estimated to be worth circa $24bln per annum by 2027, and when combined with Sanofi's development expertise our programme has the potential to address a number of indications.”

“This is the second significant agreement for a C4XD programme and marks a major milestone for the Company, not only validating the strength of our Drug Discovery expertise, but also our strategy to drive shareholder value through early-stage revenue generating deals.”

This is not the first deal with a major pharmaceutical signed by C4X. In 2018 the company signed a licensing agreement with Indivior PLC (LON:INDV) worth up to $294mln to help treat addiction. That drug is currently in a phase 1 clinical trial for treatment of opioid use disorder.

“With Indivior progressing our molecule for opioid addiction through a Phase I clinical trial and now our partnership with Sanofi driving potential next generation oral IL-17 therapies, we look forward with confidence to further develop our portfolio and deliver additional novel small molecule drug candidates tackling significant patient needs,” Dix added.

At 09:40BST, C4X shares were up 12.5% at 45.00p per share. Sanofi shares were unchanged at €85.12.

Latest comments

india
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.